Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Lountos GT, Jobson AG, Tropea JE, Self CR, Zhang G, Pommier Y, Shoemaker RH, Waugh DS.

J Struct Biol. 2011 Dec;176(3):292-301. doi: 10.1016/j.jsb.2011.09.008. Epub 2011 Sep 22.

2.

X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.

Lountos GT, Jobson AG, Tropea JE, Self CR, Zhang G, Pommier Y, Shoemaker RH, Waugh DS.

FEBS Lett. 2011 Oct 20;585(20):3245-9. doi: 10.1016/j.febslet.2011.08.050. Epub 2011 Sep 7.

3.

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y.

J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9.

4.

Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS.

Protein Sci. 2009 Jan;18(1):92-100. doi: 10.1002/pro.16.

5.

Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.

Jobson AG, Willmore E, Tilby MJ, Mistry P, Charlton P, Austin CA.

Cancer Chemother Pharmacol. 2009 Apr;63(5):889-901. doi: 10.1007/s00280-008-0812-9. Epub 2008 Aug 5.

PMID:
18679685
6.

Detection of in vitro kinase generated protein phosphorylation sites using gamma[18O4]-ATP and mass spectrometry.

Zhou M, Meng Z, Jobson AG, Pommier Y, Veenstra TD.

Anal Chem. 2007 Oct 15;79(20):7603-10. Epub 2007 Sep 18.

PMID:
17877366
7.

Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.

Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y.

Mol Pharmacol. 2007 Oct;72(4):876-84. Epub 2007 Jul 6. Erratum in: Mol Pharmacol. 2008 Oct;74(4):1170.

PMID:
17616632
8.

Repair of topoisomerase I-mediated DNA damage.

Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C.

Prog Nucleic Acid Res Mol Biol. 2006;81:179-229. Review. No abstract available.

Supplemental Content

Loading ...
Support Center